Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Antimicrob Agents Chemother
2011 Feb 01;552:879-87. doi: 10.1128/AAC.00623-10.
Show Gene links
Show Anatomy links
Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir.
Moss DM
,
Kwan WS
,
Liptrott NJ
,
Smith DL
,
Siccardi M
,
Khoo SH
,
Back DJ
,
Owen A
.
???displayArticle.abstract???
The identification of transporters of the HIV integrase inhibitor raltegravir could be a factor in an understanding of the pharmacokinetic-pharmacodynamic relationship and reported drug interactions of raltegravir. Here we determined whether raltegravir was a substrate for ABCB1 or the influx transporters SLCO1A2, SLCO1B1, SLCO1B3, SLC22A1, SLC22A6, SLC10A1, SLC15A1, and SLC15A2. Raltegravir transport by ABCB1 was studied with CEM, CEM(VBL100), and Caco-2 cells. Transport by uptake transporters was assessed by using a Xenopus laevis oocyte expression system, peripheral blood mononuclear cells, and primary renal cells. The kinetics of raltegravir transport and competition between raltegravir and tenofovir were also investigated using SLC22A6-expressing oocytes. Raltegravir was confirmed to be an ABCB1 substrate in CEM, CEM(VBL100), and Caco-2 cells. Raltegravir was also transported by SLC22A6 and SLC15A1 in oocyte expression systems but not by other transporters studied. The K(m) and V(max) for SLC22A6 transport were 150 μM and 36 pmol/oocyte/h, respectively. Tenofovir and raltegravir competed for SLC22A6 transport in a concentration-dependent manner. Raltegravir inhibited 1 μM tenofovir with a 50% inhibitory concentration (IC(50)) of 14.0 μM, and tenofovir inhibited 1 μM raltegravir with an IC(50) of 27.3 μM. Raltegravir concentrations were not altered by transporter inhibitors in peripheral blood mononuclear cells or primary renal cells. Raltegravir is a substrate for SLC22A6 and SLC15A1 in the oocyte expression system. However, transport was limited compared to endogenous controls, and these transporters are unlikely to have a great impact on raltegravir pharmacokinetics.
Anderson,
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
2008, Pubmed
Anderson,
Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects.
2008,
Pubmed
Barau,
High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.
2010,
Pubmed
Bleasby,
Expression profiles of 50 xenobiotic transporter genes in humans and pre-clinical species: a resource for investigations into drug disposition.
2006,
Pubmed
Calcagno,
Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients.
2010,
Pubmed
Chirch,
Treatment of HIV infection with raltegravir.
2009,
Pubmed
Dixit,
Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions.
2007,
Pubmed
Elsby,
Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions.
2008,
Pubmed
Espeseth,
HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase.
2000,
Pubmed
Foisy,
Induction effects of ritonavir: implications for drug interactions.
2008,
Pubmed
Hanley,
Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir.
2009,
Pubmed
Hariparsad,
Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital.
2004,
Pubmed
Hartkoorn,
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms.
2010,
Pubmed
,
Xenbase
Huang,
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.
2008,
Pubmed
Hubatsch,
Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers.
2007,
Pubmed
Iaccino,
The aftermath of the Merck's HIV vaccine trial.
2008,
Pubmed
Iwamoto,
Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.
2008,
Pubmed
Iwamoto,
Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
2008,
Pubmed
Iwamoto,
Effects of omeprazole on plasma levels of raltegravir.
2009,
Pubmed
Iwamoto,
Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation.
2008,
Pubmed
Janneh,
Intracellular accumulation of efavirenz and nevirapine is independent of P-glycoprotein activity in cultured CD4 T cells and primary human lymphocytes.
2009,
Pubmed
Kassahun,
Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.
2007,
Pubmed
Kis,
The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters.
2010,
Pubmed
Lee,
HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter.
1998,
Pubmed
Liptrott,
The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC.
2009,
Pubmed
Markowitz,
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
2006,
Pubmed
Mosmann,
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
1983,
Pubmed
Rizwan,
Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles.
2007,
Pubmed
Sobczak,
Endogenous transport systems in the Xenopus laevis oocyte plasma membrane.
2010,
Pubmed
,
Xenbase
Steigbigel,
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials.
2010,
Pubmed
Summa,
Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection.
2008,
Pubmed
Takeda,
Human organic anion transporters and human organic cation transporters mediate renal antiviral transport.
2002,
Pubmed
Uwai,
Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).
2007,
Pubmed
Wenning,
Lack of a significant drug interaction between raltegravir and tenofovir.
2008,
Pubmed
Wenning,
Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
2009,
Pubmed
Xie,
Control of steroid, heme, and carcinogen metabolism by nuclear pregnane X receptor and constitutive androstane receptor.
2003,
Pubmed
Yilmaz,
Raltegravir cerebrospinal fluid concentrations in HIV-1 infection.
2009,
Pubmed
Zhang,
In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.
2005,
Pubmed
Zhu,
Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals.
2010,
Pubmed
van der Sandt,
Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.
2001,
Pubmed
